Published in Clin Gastroenterol Hepatol on December 01, 2016
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
Publication bias in clinical research. Lancet (1991) 22.85
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Meta-analysis: principles and procedures. BMJ (1997) 6.87
Intestinal inflammation and cancer. Gastroenterology (2011) 4.13
Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology (1994) 3.44
GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol (2011) 3.02
SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology (2015) 2.87
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol (2012) 2.73
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc (2014) 2.46
Cancer surveillance in ulcerative colitis. Gastroenterology (1991) 1.93
Failure of colonoscopic surveillance in ulcerative colitis. Gut (1993) 1.82
Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology (1995) 1.80
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol (2001) 1.71
Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg (2014) 1.58
Colonoscopic surveillance in long-standing total ulcerative colitis--a 15-year follow-up study. Gastroenterology (1990) 1.43
Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther (2007) 1.35
Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut (2003) 1.32
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer (2003) 1.25
Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology (1988) 1.16
Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum (2002) 1.14
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol (2007) 1.10
Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity. Gut (2009) 1.00
Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol (1996) 0.97
Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis (2013) 0.96
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis (2010) 0.90
Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut (2014) 0.90
Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer. Am J Gastroenterol (2015) 0.89
Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflamm Bowel Dis (2011) 0.87
Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance. Clin Gastroenterol Hepatol (2015) 0.87
Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm Bowel Dis (2012) 0.85
The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. Aliment Pharmacol Ther (2013) 0.83
Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis (2013) 0.82
Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology (2015) 0.81
Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. Gastrointest Endosc (2011) 0.81
Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. Dis Colon Rectum (2014) 0.79
Cancers Complicating Inflammatory Bowel Disease. N Engl J Med (2015) 0.79
Cancer prevention in ulcerative colitis: long-term outcome following fluorescence-guided colonoscopy. Inflamm Bowel Dis (2011) 0.78
Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohns Colitis (2013) 0.78
Ulcerative colitis with low-grade dysplasia. Gastroenterology (2004) 0.77
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology (2013) 2.97
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA (2016) 1.78
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology (2014) 1.57
Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol (2014) 1.42
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology (2014) 1.35
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology (2013) 1.12
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol (2015) 1.10
Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol (2014) 0.84
Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol (2017) 0.76
Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila) (2016) 0.75
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol (2016) 0.75
Reply. Clin Gastroenterol Hepatol (2015) 0.75
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology (2019) 0.75
Magnitude and Kinetics of Decrease in Liver Stiffness After Anti-viral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol (2017) 0.75
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol (2017) 0.75
Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. J Crohns Colitis (2017) 0.75
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol (2020) 0.75